EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial

Carlos M Grilo, Valentina Ivezaj, Cenk Tek, Sydney Yurkow, Ashley A Wiedemann, Ralitza Gueorguieva

American Journal of Psychiatry · 01.02.2025 · 182 (2) · 209-218

DOI: 10.1176/appi.ajp.20230982 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Psychiatry, erschienen am 01.02.2025. Verfasst von Carlos M Grilo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven (Grilo, Ivezaj, Tek, Yurkow, Wiedemann); Department of Biostatistics, Yale Sc…. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Lisdexamfetamine Dimesylate, Cognitive Behavioral Therapy, Obesity. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Binge-eating disorder (BED) is a prevalent, costly public health problem associated with serious functional impairments and heightened rates of psychiatric and medical comorbidities. Few evidence-based treatments are currently available for BED. We tested the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED comorbid with obesity. METHODS: Randomized controlled trial was conducted March 2019 to September 2023 at a single site. N=141 patients with BED (83.7% women, mean age 43.6, mean BMI 38.6 kg/m2) were randomized to one of three 12-week treatments: CBT (N=47), LDX (N=47), or CBT+LDX (N=47); 87.2% completed independent posttreatment assessments. RESULTS: Mixed models revealed binge-eating frequency decreased significantly in all treatments, with CBT+LDX having the largest reduction and significantly outperforming CBT and LDX, which did not differ. Intention-to-treat binge-eating remission rates differed significantly between treatments, with CBT+LDX having the highest remission rate (70.2%) followed by CBT (44.7%) and LDX (40.4%). Mixed models revealed percent weight loss increased significantly throughout treatment with LDX and CBT+LDX but remained unchanged in CBT. LDX and CBT+LDX had significantly greater percent weight loss than CBT starting after one month and through posttreatment. Intention-to-treat rates of attaining ≥5% weight loss differed across treatments, with LDX having the highest (53.2%), followed by CBT+LDX (42.6%) and CBT (4.3%). Analyses revealed significant reductions in eating-disorder psychopathology; CBT+LDX had largest reductions and significantly outperformed CBT and LDX. CONCLUSIONS: CBT, LDX, and CBT+LDX showed significant improvements in BED, with a consistent pattern of the combined CBT+LDX being superior to the two individual treatments, which differed little.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Binge-Eating DisorderLisdexamfetamine DimesylateCognitive Behavioral TherapyObesityCentral Nervous System StimulantsHumansFemaleAdultMaleCombined Modality TherapyMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

CognitivePsychotherapybinge eatingcognitive behavioral therapyeating disordersobesitypharmacotherapyweight loss

Substanzen

Lisdexamfetamine DimesylateCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Psychiatry, Yale University School of Medicine, New Haven (Grilo, Ivezaj, Tek, Yurkow, Wiedemann); Department of Biostatistics, Yale School of Public Health, New Haven (Gueorguieva).

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Grilo, C. M., Ivezaj, V., Tek, C., Yurkow, S., Wiedemann, A. A., & Gueorguieva, R. (2025). Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal of Psychiatry, 182(2), 209-218. https://doi.org/10.1176/appi.ajp.20230982

Vancouver

Grilo CM, Ivezaj V, Tek C, Yurkow S, Wiedemann AA, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal of Psychiatry. 2025;182(2):209-218. doi:10.1176/appi.ajp.20230982

BibTeX
@article{Grilo2025,
  author = {Grilo, Carlos M and Ivezaj, Valentina and Tek, Cenk and Yurkow, Sydney and Wiedemann, Ashley A and Gueorguieva, Ralitza},
  title = {Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial},
  journal = {American Journal of Psychiatry},
  year = {2025},
  volume = {182},
  number = {2},
  pages = {209--218},
  doi = {10.1176/appi.ajp.20230982}
}
Kostenlos starten →